The synergistic effect of ginkgetin and cisplatin (DDP) inactivated the NRF2/HO-1 axis, enhancing ferroptosis in NSCLC by downregulating SLC7A11 and GPX4 expression, promoting the anticancer effects of cisplatin [83]. The gene discussed is GPX4; the disease is non-small cell lung carcinoma.